Therapy News and Research

RSS

St. Luke's Episcopal Hospital uses CyberKnife robotic radiosurgery system for treating tumours

St. Luke's Episcopal Hospital is the first hospital in Houston to feature the CyberKnife((R)), a noninvasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors.

2 Sep 2009

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients receiving only an implanted cardiac defibrillator (ICD), according to a landmark study published online today in the New England Journal of Medicine and presented today at the European Society of Cardiology Congress (ESC) in Barcelona, Spain.

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Current European practice and routines associated with the implantation of a CRT device described

The European cardiac resynchronization therapy (CRT) Survey is a joint initiative taken by the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology.

2 Sep 2009

Primary angioplasty procedures vary in European countries

Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.

2 Sep 2009

Telemedical supervision for chronic heart failure patients reduces hospital expenses

The current data confirms previous health economic evaluations: If patients with chronic heart failure are receive telemedical supervision, this means that they will require less and shorter hospital care. In this study hospital expenses dropped by around 70 percent in a year.

2 Sep 2009

$Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed$

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

This week TCA Cellular Therapy`s Medical Director Gabriel Lasala, M.D. presents advances in adult stem cell treatments for severe limb ischemia and refractory coronary ischemia at the European Society of Cardiology Congress in Barcelona, Spain.

2 Sep 2009

New therapy delays the progression of heart failure

A therapy called cardiac resynchronization can significantly delay the progression of heart failure, according to a major international study published in the New England Journal of Medicine.

2 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Positive results from second pivotal phase III trial for Lodotra

Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM).

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

Nanodiamonds: A novel gene delivery technology

Gene therapy holds promise in the treatment of a myriad of diseases, including cancer, heart disease and diabetes, among many others. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging.

2 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

Policymakers need to be educated on the radical difference between radiation therapy and diagnostic testing

Concerned members of the cancer community, including physicians, patient organizations and other care advocates, spoke out today in opposition to a proposed federal policy under consideration by the Centers for Medicare and Medicaid Services (CMS) that would lump life-saving radiation therapy in with diagnostic testing services in receiving major Medicare funding cuts.

2 Sep 2009

Eating Recovery Center releases white paper on referral practices

Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today released a white paper, "Eating Recovery Center's Report on Referral Practices: Recent Research Reveals Trends in the Process of Referrals for Eating Disordered Patients."

2 Sep 2009

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p<0.001, RRR = 16%), without an increase in major bleeding.

2 Sep 2009

Pathogenic microbes can suppress immune system in newborns

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

2 Sep 2009

Therapy News and Research

St. Luke's Episcopal Hospital uses CyberKnife robotic radiosurgery system for treating tumours

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Current European practice and routines associated with the implantation of a CRT device described

Primary angioplasty procedures vary in European countries

Telemedical supervision for chronic heart failure patients reduces hospital expenses

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

New therapy delays the progression of heart failure

New findings on molecular imaging and prostate cancer

Positive results from second pivotal phase III trial for Lodotra

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Actelion launches new 20 mcg/mL Ventavis formulation

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nanodiamonds: A novel gene delivery technology

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Policymakers need to be educated on the radical difference between radiation therapy and diagnostic testing

Eating Recovery Center releases white paper on referral practices

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

Pathogenic microbes can suppress immune system in newborns

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News